$KRMD

KORU Medical Systems (KRMD) reported Q2 PST revenue of $0.6M, down 35% year over year, citing lower clinical-trial orders and timing. Gross margin rose to 65.1% from 63.5%. The company narrowed full-year revenue guidance to $47.5M-$48.5M, raised gross-margin guidance to 62%-64%, ended with $8.3M cash, and expects positive adjusted EBITDA. It acquired a connected monitoring technology asset and shifted some FDA oncology timing.

KORU Medical Systems reported Q2 2026 revenue up 18% and first positive net income since 2019, with domestic revenue up 12% and international revenue up 59%. It withdrew a US FDA 510(k) for Phesgo, narrowed FY revenue guidance to $47.5M-$48.5M, raised gross margin to 62%-64%, and expects positive adjusted EBITDA in 2026.

KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99 2 ex_99-1.htm PRESS RELEASE, DATED AUGUST 5, 2026 EXHIBIT 99.1 KORU Medical Systems Announces Second Quarter 2026 Results and Updates Full Year 2026 Guidance MAHWAH, NJ – August 5, 2026 – KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading

KORU Medical Systems, Inc. (KRMD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10 2 ex_10-1.htm AMENDMENT NO. 1 TO AMENDED & RESTATED MANUFACTURING & SUPPLY AGREEMENT Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND THE EXC

KALBERMATTEN ADAM R (President-Chief Commercial Off) purchased 12,500 shares of KORU Medical Systems, Inc. (KRMD) at an average of $3.94 ($3.93–$3.96) across 2 trades on 2026-06-11.

KORU Medical Systems, Inc. (NASDAQ:KRMD) published its slide deck in conjunction with its 2026 Q1 earnings call. This presentation provides details discussed during the call for investors and interested parties. The content was prepared by Seeking Alpha's transcripts team.

KORU Medical Systems announced strong first-quarter 2026 financial results, with net revenues increasing by 22% and gross profit by 20%. The company reiterated its full-year 2026 guidance, expecting continued growth in net revenues and positive adjusted EBITDA. Notably, KORU submitted a 510(k) application for its Freedom Infusion System for use with Deferoxamine, and two of its non-Ig pharma collaborations have advanced to Phase III clinical trials, highlighting its expansion into new drug categories and therapy areas.

The request mentions that KORU Medical has secured EU MDR certification for its Freedom60 infusion pump. This suggests a significant regulatory achievement for the company, allowing its device to be marketed in the European Union under the new Medical Device Regulation. The article content, however, is not provided, so further details are unavailable.

Koru Medical Systems is projecting revenue between $47.5 million and $50 million for 2026, driven by new leadership and an acceleration of international expansion efforts. The company is actively working to grow its market presence and financial performance in the coming years.

KORU Medical Systems announced that its Freedom60® Infusion Pump, designed for use with 50 mL prefilled syringes, has received EU MDR certification. This certification allows for commercialization across the EU and expands access to its system, which supports the growing use of prefilled syringes in subcutaneous immunoglobulin (SCIg) therapy. The company emphasizes that this advancement simplifies home infusion for patients and offers flexibility in dosing regimens, building on features that reduce preparation and improve patient independence.